YourEra Review
Best for: patients comfortable with a $99 first-month entry price who are willing to confirm steady-state ongoing pricing at checkout before committing
YourEra (yourera.com) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide and compounded tirzepatide injection programs starting at $99 for the first month. Steady-state monthly pricing is gated behind the medical intake. The site explicitly states the medications are NOT the brand-name drugs Ozempic, Wegovy, Mounjaro, or Zepbound. Pharmacy partners are described generically as 'state-licensed pharmacies that follow applicable state and federal regulations' but specific names are not disclosed.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
YourEra is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
YourEra prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide (first month) | compounded | $99 |
| Compounded tirzepatide (first month) | compounded | $99 |
✓ Pros
- •$99 first-month entry pricing for compounded GLP-1 access is competitive with the cheapest decile of the US compounded telehealth market
- •LegitScript Certified seal displayed in the footer (the standard third-party telehealth/pharmacy accreditation)
- •100% online doctor visits and prescriptions disclosed clearly
- •Site is honest that the compounded medications are NOT the brand-name Ozempic/Wegovy/Mounjaro/Zepbound — material YMYL transparency
✗ Cons
- •Steady-state ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
- •Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
- •Pharmacy partners NOT publicly named (described generically as 'state-licensed pharmacies')
- •Per-state availability NOT enumerated; verify your state ships before purchase
- •Initial consultation fee structure NOT disclosed publicly
- •Lab work + ongoing-care touchpoints NOT clearly disclosed in marketing copy
Ready to start with YourEra?
Starting at $99/month. See current pricing and start your free consultation.
Sources & methodology
Our YourEra review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to YourEra
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with YourEra?
Starting at $99/month. See current pricing and start your free consultation.